+

WO2010113860A1 - Composé biphényle-amine cyclique - Google Patents

Composé biphényle-amine cyclique Download PDF

Info

Publication number
WO2010113860A1
WO2010113860A1 PCT/JP2010/055546 JP2010055546W WO2010113860A1 WO 2010113860 A1 WO2010113860 A1 WO 2010113860A1 JP 2010055546 W JP2010055546 W JP 2010055546W WO 2010113860 A1 WO2010113860 A1 WO 2010113860A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
compound
pharmacologically acceptable
acceptable salt
halogeno
Prior art date
Application number
PCT/JP2010/055546
Other languages
English (en)
Japanese (ja)
Inventor
彰 中尾
建徳 五反田
一真 青木
悟 金子
健 有田
哲平 藤本
由晴 昼間
剛史 椎木
マーチン コートニー ステファン
ジョン ヤーノルド クリストファー
デービー レベッカ
セルバラトナム スガンタン
Original Assignee
第一三共株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 第一三共株式会社 filed Critical 第一三共株式会社
Publication of WO2010113860A1 publication Critical patent/WO2010113860A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/20—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to a compound having a calcium-sensing receptor (CaSR, hereinafter simply referred to as a calcium receptor) antagonistic action.
  • CaSR calcium-sensing receptor
  • Bone is known as a dynamic organ that constantly remodels and resorbs and remodels to maintain its own morphological changes and blood calcium levels.
  • bone formation by osteoblasts and bone resorption by osteoclasts are in an equilibrium relationship, and the bone mass is kept constant.
  • bone metabolism abnormalities such as osteoporosis occur (Non-Patent Documents 1 and 2).
  • Non-Patent Documents 3 and 4 A number of systemic hormones and local cytokines have been reported as factors that regulate bone metabolism, and bone formation and maintenance are carried out by the joint action of these factors.
  • Non-Patent Documents 3 and 4 The development of osteoporosis is widely known as a change in bone tissue due to aging, but the mechanism of its onset is decreased secretion of sex hormones and receptor abnormalities, fluctuations in cytokine expression in bone, aging gene expression, osteoclast It is difficult to understand as a simple physiological phenomenon due to aging due to a variety of cells and osteoblast differentiation and dysfunction.
  • Primary osteoporosis is roughly classified into postmenopausal osteoporosis due to decreased estrogen secretion and senile osteoporosis due to aging. In order to elucidate the onset mechanism and develop therapeutic agents, the mechanism of regulation of bone resorption and bone formation Progress in basic research is essential.
  • Osteoclasts are multinucleated cells derived from hematopoietic stem cells that release the chloride and hydrogen ions on the bone-adherent surface, thereby acidifying the gap between the cell-bone adhesive surface and being an acidic protease. Cathepsin K and the like are secreted (Non-patent Document 5). As a result, the degradation of bone matrix protein and calcium phosphate is induced, and calcium mobilization into the blood occurs.
  • Serum calcium concentration in normal mammals is strictly maintained at about 9-10 mg / dl (about 2.5 mM) (calcium homeostasis).
  • Parathyroid hormone (PTH) is a hormone that plays a central role in maintaining calcium homeostasis, and PTH secretion from the parathyroid gland is immediately promoted when the blood Ca 2+ concentration decreases.
  • the secreted PTH mobilizes Ca 2+ into the blood by promoting bone resorption in the bone and the blood in the kidney by promoting resorption of Ca 2+ in the distal tubule. It has the function of increasing the medium Ca 2+ concentration.
  • PTH is known to increase bone mass when intermittently administered to humans and animals, and has already been clinically applied as a therapeutic agent for osteoporosis.
  • continuous administration of bovine PTH (1-84) to thyroid / parathyroidectomized rats promotes both cancellous bone formation and bone resorption in the femur and decreases net bone mass.
  • bone resorption is not enhanced, only bone formation is enhanced, and bone mass is increased (Non-patent Document 6).
  • human PTH (1-34) was intermittently administered to the ovariectomized rats from the 4th week to 15 weeks after the operation, the bone formation was enhanced and the bone resorption was suppressed from the 5th week to the 10th week after the start of the administration.
  • Non-patent Document 7 It was reported that the bone mass increased to about twice that of the sham operation group (Non-patent Document 7). This report suggests that PTH not only prevents bone loss in osteoporosis models, but also has an effect of restoring bone mass in animals where bone loss has already occurred prominently.
  • PTH preparation is an osteoporosis therapeutic agent that has been confirmed to have a remarkable fracture rate-reducing effect in clinical trials for postmenopausal osteoporosis patients, but has a disadvantage because it is a biological preparation. That is, injection must be adopted as an administration means, and the problem remains that it is painful for many patients. Therefore, the development of an orally administrable drug that can intermittently increase the PTH concentration in the blood is awaited.
  • the calcium receptor is a G protein-coupled receptor mainly expressed in parathyroid cells, and regulates PTH secretion by sensing blood Ca 2+ concentration (Non-patent Document 8).
  • the human calcium receptor is composed of 1078 amino acids and has been reported to be expressed in kidney, thyroid C cells, brain and bone marrow cells in addition to the parathyroid gland.
  • the calcium receptor binds to the ligand Ca 2+, it couples with the G protein and activates phospholipase C, leading to production of inositol triphosphate and an increase in intracellular Ca 2+ concentration, and as a result, the secretion of PTH is suppressed.
  • Non-Patent Document 9 a drug that inhibits activation of the calcium receptor, that is, a drug that antagonizes the calcium receptor is expected to promote PTH secretion from parathyroid cells and increase the blood PTH concentration in vivo.
  • the biphenyl-cyclic amine compound of the present invention is a compound having a calcium receptor antagonistic action.
  • having calcium receptor antagonism is meant reducing one or more calcium receptor activities induced by extracellular Ca 2+ .
  • the present invention (1) A compound having the general formula (I) or a pharmacologically acceptable salt thereof.
  • R 1 hydrogen atom, hydroxyl group, halogen atom, C1-C6 alkyl group, C1-C6 alkoxy group, halogeno C1-C6 alkyl group or C7-C11 aralkyloxy group
  • R 1 ′ hydrogen atom, hydroxyl group, halogen atom, C1- C6 alkyl group, C1-C6 alkoxy group, halogeno C1-C6 alkyl group or C7-C11 aralkyloxy group (or R 1 and R 1 ′ together are a C1-C3 alkylene group)
  • R 2 hydrogen atom, halogen atom, C1-C6 alkyl group, C1-C6 alkoxy group, halogeno C1-C6 alkyl group or halogeno C1-C6 alkoxy group
  • R 1 and R 1 ′ are a hydrogen atom, a hydroxyl group, a fluorine atom, a chlorine atom, a methoxy group or a benzyloxy group.
  • R 2 is a hydrogen atom.
  • R 3 is a hydrogen atom, a nitro group, a fluorine atom, a chlorine atom, a methyl group, an ethyl group or a methoxy group, the compound according to any one selected from (1) to (3) or a pharmacologically thereof Acceptable salt.
  • R 1 and R 1 ′ are a hydrogen atom, a hydroxyl group, a fluorine atom, a chlorine atom, a methoxy group or a benzyloxy group.
  • the compound according to any one of (1) to (8) or a pharmacologically acceptable salt thereof for use as a calcium receptor antagonist (10) (1) A pharmaceutical composition comprising as an active ingredient the compound described in any one of (8) or a pharmacologically acceptable salt thereof. (11) The pharmaceutical composition according to (10) for use as a calcium receptor antagonist. (12) The pharmaceutical composition according to (10) for use in treating or preventing a disease associated with abnormal bone or mineral homeostasis.
  • Diseases associated with abnormal bone or mineral homeostasis include hypoparathyroidism; osteosarcoma; periodontal disease; fracture healing; osteoarthritis; rheumatoid arthritis; Paget's disease; The pharmaceutical composition according to (12), which is accompanied by humoral hypercalcemia; or; osteoporosis.
  • the pharmaceutical composition according to (12), wherein the disease associated with abnormal bone or mineral homeostasis is osteoporosis.
  • a method for improving bone metabolism comprising administering an effective amount of the pharmaceutical composition described in (10) to a mammal.
  • a method for preventing or treating osteoporosis comprising administering an effective amount of the pharmaceutical composition described in (10) to a mammal.
  • the compound of the present invention or a pharmacologically acceptable salt thereof acts as a calcium receptor antagonist, thereby causing diseases associated with abnormal bone or mineral homeostasis, such as hypoparathyroidism, osteosarcoma, periodontal disease It is useful for the treatment or prevention of humoral hypercalcemia and osteoporosis associated with fracture healing, osteoarthritis, rheumatoid arthritis, Paget's disease, malignancy and fracture healing.
  • the compound having the general formula (I) is preferably a compound having the following combinations as substituents.
  • R 1 and R 1 ′ are a hydrogen atom, a hydroxyl group, a fluorine atom, a chlorine atom, a methoxy group or a benzyloxy group
  • R 2 is a hydrogen atom
  • R 3 is a hydrogen atom, a nitro group, a fluorine atom, a chlorine atom, a methyl group, an ethyl group or a methoxy group
  • Ar is a phenyl group which may be substituted with a group selected from a methyl group, a fluorine atom and a chlorine atom
  • n is 0 or 1
  • m is 0, 1, or 2.
  • More preferable examples of the compound having the general formula (I) include the compounds described in Examples.
  • the “halogen atom” is, for example, a fluorine atom, a chlorine atom, a bromine atom or an iodine atom, and preferably a fluorine atom or a chlorine atom.
  • the “C1-C6 alkyl group” is a linear or branched alkyl group having 1 to 6 carbon atoms, preferably a methyl group, an ethyl group, a propyl group, an isopropyl group, or a t-butyl group. More preferably, it is a methyl group.
  • the “C1-C6 alkoxy group” is a group in which an oxygen atom is bonded to the C1-C6 alkyl group, preferably a methoxy group, an ethoxy group, a propoxy group, an isopropoxy group, or a t-butoxy group. More preferably, it is a methoxy group.
  • the “halogeno C1-C6 alkyl group” is a group obtained by substituting a halogen atom for the C1-C6 alkyl group.
  • the “halogeno C1-C6 alkoxy group” is a group obtained by substituting a halogen atom for the C1-C6 alkoxy group.
  • the “C4-C10 aryl group” is a cyclic aromatic group having 4 to 10 carbon atoms, for example, an aromatic hydrocarbon group having 6 to 10 carbon atoms such as phenyl, indenyl, naphthyl (preferably, Phenyl group), furyl, thienyl, pyrrolyl, azepinyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, 1,2,3-oxadiazolyl, 1,3,4-oxadiazolyl, triazolyl, tetrazolyl, thiadiazolyl, pyranyl, pyridyl, Aromatic heterocyclic groups such as pyridazinyl, pyrimidinyl, pyrazinyl, benzothienyl, isobenzofuranyl, chromenyl, xanthenyl, phenoxathiinyl,
  • the “C7-C11 aralkyloxy group” is a group obtained by substituting a methylene group for the C4-C10 aryl group, and is preferably a benzyl group, for example.
  • the “C1-C3 alkylene group” is a methylene group, an ethylene group or a propylene group.
  • the “halogeno C1-C3 alkylenedioxy group” is a C 1-3 alkylenedioxy group substituted with a halogen atom, and includes, for example, a difluoromethylenedioxy group. “Treatment” means curing or ameliorating a disease or condition or suppressing a symptom.
  • the “pharmacologically acceptable salt” refers to a salt that can be used as a medicine. In the compound of this invention, when it has an acidic group or a basic group, since it can be made into a basic salt or an acidic salt by making it react with a base or an acid, the salt is shown.
  • the pharmacologically acceptable “basic salt” of the compound of the present invention is preferably an alkali metal salt such as sodium salt, potassium salt or lithium salt; an alkaline earth metal salt such as magnesium salt or calcium salt.
  • Organic base salts such as N-methylmorpholine salt, triethylamine salt, tributylamine salt, diisopropylethylamine salt, dicyclohexylamine salt, N-methylpiperidine salt, pyridine salt, 4-pyrrolidinopyridine salt, picoline salt or glycine salt; Amino acid salts such as lysine salts, arginine salts, ornithine salts, glutamates, and aspartates, and alkali metal salts are preferred.
  • the pharmacologically acceptable “acid salt” of the compound of the present invention is preferably a hydrohalide salt such as hydrofluoride, hydrochloride, hydrobromide, hydroiodide, Inorganic acid salts such as nitrates, perchlorates, sulfates, phosphates; lower alkane sulfonates such as methanesulfonate, trifluoromethanesulfonate, ethanesulfonate, benzenesulfonate, p- Organics such as aryl sulfonates such as toluene sulfonate, acetate, malate, fumarate, succinate, citrate, ascorbate, tartrate, oxalate, maleate, etc. Acid salts; and amino acid salts such as glycine salt, lysine salt, arginine salt, ornithine salt, glutamate salt, aspartate, and most preferably hydrohalide salt.
  • the compound of the present invention or a pharmacologically acceptable salt thereof may absorb moisture, adhere to adsorbed water, or become a hydrate when left in the air or by recrystallization.
  • the present invention also includes such various hydrates, solvates and polymorphic compounds.
  • the light compounds of the present invention, salts thereof or solvates thereof may be isomers such as cis isomers and trans isomers, tautomers or optical isomers such as d isomers and l isomers, depending on the type and combination of substituents.
  • the compounds of the present invention include all isomers, stereoisomers and any ratios of these isomers and stereoisomer mixtures, unless otherwise specified. Is. A mixture of these isomers can be separated by a known resolution means.
  • the compound of the present invention also includes a label, that is, a compound in which one or more atoms of the compound of the present invention are substituted with a radioisotope (for example, 3 H, 14 C, 35 S, etc.).
  • the present invention also includes pharmacologically acceptable prodrugs of the compounds of the present invention.
  • a pharmacologically acceptable prodrug is a compound having a group that can be converted into an amino group, a hydroxyl group, a carboxyl group, or the like of the compound of the present invention by hydrolysis or under physiological conditions.
  • Drug-forming groups are described in Prog. Med., Volume 5, pages 2157-2161, 1985, “Development of Drugs” (Yodogawa Shoten, 1990), Volume 7, Molecular Design pages 163-198 It is the basis of.
  • the prodrug more specifically, when an amino group is present in the compound of the present invention, a compound in which the amino group is acylated, alkylated or phosphorylated (for example, the amino group is eicosanoylated).
  • hydroxyl group is present in the compound of the present invention, a compound in which the hydroxyl group is acylated, alkylated, phosphorylated or borated (for example, The hydroxyl group is acetylated, palmitoylated, propanoylated, pivaloylated, succinylated, fumarylated, alanylated, dimethylated.
  • a carboxy group is present in the compound of the present invention, a compound in which the carboxy group is esterified or amidated (for example, the carboxy group is ethyl esterified, phenyl esterified, carboxymethyl esterified, dimethyl Aminomethyl esterification, pivaloyloxymethyl esterification, ethoxycarbonyloxyethyl esterification, amidation, or methylamidated compounds, etc.).
  • the compound of the present invention can be produced by applying various known synthesis methods using characteristics based on the basic skeleton or the type of substituent.
  • Known methods include, for example, the methods described in “ORGANIC FUNCTIONAL GROUP PREPARATIONS”, 2nd edition, ACADEMIC PRESS, INC., 1989, “Comprehensive Organic Transformations”, VCH Publishers Inc., 1989, and the like.
  • it is effective in terms of production technology to protect the functional group with a suitable protecting group at the raw material or intermediate stage, or to replace it with a group that can be easily converted to the functional group. There are cases.
  • Examples of such a functional group include an amino group, a hydroxyl group, a carboxyl group, and the like, and examples of the protecting group include Protective Groups in Organic Synthesis (3rd edition, 1999) by TW Greene and PG Wuts. May be appropriately selected depending on these reaction conditions.
  • the desired compound after carrying out the reaction by introducing the substituent, the desired compound can be obtained by removing the protective group or converting it to a desired group as necessary.
  • a prodrug of the compound of the present invention is produced by introducing a specific group at the raw material or intermediate stage, or reacting with the obtained compound of the present invention, in the same manner as the above protecting group. it can.
  • the reaction can be carried out by applying methods known to those skilled in the art, such as ordinary esterification, amidation, dehydration, hydrogenation and the like.
  • the production method of the compound of the present invention is described below. However, the manufacturing method is not limited to the following method.
  • R 1 , R 1 ′ , Ar, n are as defined above, and PG represents an amino-protecting group.
  • the first step is a condensation reaction of carboxylic acid and hydroxyamine, and is a step of producing compound (2) from compound (1).
  • the second step is a step of producing a compound (3) which is a ketone by reacting a compound (2) with a Grignard reagent.
  • the third step is a step of obtaining compound (4) by reducing compound (3).
  • the first to third steps are carried out according to the method described in Zhou et al., Heteroatom Chemistry 2003, 14, 603-606.
  • Steps 4 to 6 are steps for producing compound (7) from compound (4).
  • the Barton-McCombie Reaction of the fourth step and the fifth step is described in Mulzer et al. J. Org. Chem. 1986, 51, 5294-5299.
  • the sixth step is performed by deprotecting the protecting group according to the method described in Protective Groups in Organic Synthesis (3rd edition, 1999).
  • Compound (7) can also be synthesized by the following route.
  • the seventh step is a step of producing compound (8) by phosphorylating compound (1).
  • the eighth step is a step of producing the compound (3) by using a Grignard reagent as in the second step.
  • the ninth step is a step of producing the compound (6) by reducing the ketone of the compound (3), and the tenth step is similar to the above-mentioned sixth step, in which Protective Groups in Organic Synthesis (3rd edition, 1999) by deprotecting the protecting group.
  • the seventh to tenth steps are the reaction examples described in page 16 of WO 2004/106295 and Yang et al. Bioorg. Med. Chem. Lett. 2005, 15, 1225-1228.
  • the eleventh step is a step of producing compound (10) using compound (9), which is a substituted benzoic acid, and N, O-dimethylhydroxylamine hydrochloride, which is described in Kunishima et al. Of Tetrahedron 1999, 55, 13159-13170.
  • the twelfth step can be performed in the same manner as the second step described above, and is a step of producing the compound (11) from the compound (10). Further, in step 13, compound (11) is reduced to give compound (12), and then in step 14, compound (12) and compound (13) are reacted to produce compound (14). .
  • the 12th to 14th steps are performed according to the reaction example described on page 40 of WO02 / 14259.
  • the twelfth step is performed according to the eighth step and step 23 of Example 23 described on page 49 of WO02 / 14259.
  • the thirteenth step is performed according to Example 21, step 1 described on page 66 of WO02 / 14259.
  • the 14th step is carried out in accordance with Example 1 Step 2 described on page 50 of WO02 / 14259.
  • the fifteenth to nineteenth steps can be carried out according to the reaction example described on page 77 of WO2004 / 094362.
  • the fifteenth step is a step for producing the compound (16) by protecting the carboxy group of the compound (15) with a protecting group R 4 , according to Example 1-1, step 2 described on page 99 of WO2004 / 094362. Do.
  • the sixteenth step is a step of producing compound (17) by reacting compound (16) with boric acid ester, and is produced according to Example 1-1, step 3 described on page 100 of WO2004 / 094362.
  • the seventeenth step is a step of producing compound (18) by coupling compound (17) and compound (14), and is produced according to Example 1-1, step 3 described on page 100 of WO2004 / 094362.
  • the 18th step is a step of producing the compound (19) by reacting the epoxide portion of the compound (18) with the amine of the compound (7). In Example 1-1 described in page 103 of WO2004 / 094362, Manufacture accordingly.
  • the nineteenth step is a step of producing the compound (20) by hydrolyzing the ester moiety of the compound (19), which is produced according to Example 1-1, step 9 described on page 103 of WO2004 / 094362.
  • the compound of the present invention produced by the above method can be isolated and purified by a known method such as extraction, precipitation, distillation, chromatography, fractional recrystallization, recrystallization and the like. Further, when the compound having the general formula (I) of the present invention or the intermediate of production has an asymmetric carbon, an optical isomer exists. These optical isomers can be isolated and purified by conventional methods such as fractional recrystallization (salt resolution) recrystallizing with an appropriate salt and column chromatography. References for a method for resolving optical isomers from racemates include “Enantiomers, Racemates and Resolution, John Wiley And Sons, Inc.” by J. Jacques et al.
  • the compound of the present invention or a pharmacologically acceptable salt thereof is administered to a mammal (particularly human), it can be administered systemically or locally, orally or parenterally.
  • the pharmaceutical composition of the present invention can be produced by selecting an appropriate form according to the administration method and preparing various preparations usually used.
  • Examples of the form of the oral pharmaceutical composition include tablets, pills, powders, granules, capsules, solutions, suspensions, emulsions, syrups, elixirs and the like.
  • the preparation of these forms of pharmaceuticals includes excipients, binders, disintegrants, lubricants, swelling agents, swelling aids, coating agents, plasticizers, stabilizers, antiseptics, antiseptics commonly used as additives.
  • parenteral pharmaceutical compositions include injections, ointments, gels, creams, poultices, patches, sprays, inhalants, sprays, eye drops, nasal drops, suppositories, and inhalations. Agents and the like.
  • the preparation of these forms of pharmaceuticals involves the use of stabilizers, preservatives, solubilizers, moisturizers, preservatives, antioxidants, flavoring agents, gelling agents, neutralizing agents, dissolution agents that are commonly used as additives
  • Adjuvant, buffer, isotonic agent, surfactant, colorant, buffer, thickener, wetting agent, filler, absorption enhancer, suspending agent, binder, etc. Can be carried out according to a conventional method.
  • the dose of the compound having the general formula (I) or a pharmacologically acceptable salt thereof varies depending on the symptoms, age, body weight, type of drug to be administered in combination, dose, etc. Is it administered in the range of 0.001 mg to 1000 mg per adult (as a body weight of about 60 kg), or once or several times a day, orally or parenterally, in the equivalent amount of the compound it has? Alternatively, it is preferably administered intravenously in the range of 1 to 24 hours per day.
  • the present invention also includes a method for preventing and / or treating the aforementioned disease, which comprises administering the compound of the present invention or a pharmacologically acceptable salt thereof. Furthermore, the present invention includes the use of the compound of the present invention and a pharmacologically acceptable salt thereof for producing the pharmaceutical composition.
  • Formulation Example 1 (Powder) The powder is obtained by mixing 5 g of the compound of the present invention, 895 g of lactose and 100 g of corn starch with a blender.
  • Formulation Example 2 (granule) After mixing 5 g of the compound of the present invention, 865 g of lactose and 100 g of low-substituted hydroxypropylcellulose, 300 g of 10% hydroxypropylcellulose aqueous solution is added and kneaded. This is granulated using an extrusion granulator and dried to obtain granules.
  • Formulation Example 3 A compound is prepared by mixing 5 g of the compound of the present invention, 90 g of lactose, 34 g of corn starch, 20 g of crystalline cellulose and 1 g of magnesium stearate with a blender and then tableting with a tablet machine.
  • assay buffer (20 mM HEPES, 2.5 mM probenecid-containing HBSS (Ca and Mg-free), pH 7.4) containing Calcium 3 (manufactured by Molecular Devices), a fluorescent intracellular calcium indicator. 25 ⁇ l / well was added and allowed to stand in a CO 2 incubator for 1 hour. Calcium 3 was prepared according to the protocol attached to FLIPR Calcium 3 Assay Kit (manufactured by Molecular Devices). After standing for 1 hour, 25 ⁇ l / well of a solution prepared by adjusting the test compound to a concentration of 2.1 to 20,000 nM (final concentration: 1.05 to 10,000 nM) in assay buffer was added and placed in a CO 2 incubator.
  • the compounds shown in 25, 26, 27, 28, 29, 30, 32, 33, 34, 35, 36, 38, 40, 41, 44 showed an inhibitory activity with an IC 50 of 1.1 ⁇ g / ml or less.
  • Test Example 2 Evaluation of PTH secretion-promoting action using rats 10-14 week-old female F344 rats (Nippon Charles River) fasted overnight were collected from the jugular vein under ether anesthesia to prepare pre-dose serum. Subsequently, the test compound was orally administered at a dose of 3 mg / 5 ml / kg using a solvent (0.5% methylcellulose aqueous solution containing 5% DMA). Blood was collected from the jugular vein under ether anesthesia 5, 15, 30, 60, 120, and 240 minutes after administration of the test compound. Serum PTH concentration was measured using a rat Intact PTH ELISA kit (manufactured by Immupics).
  • the compounds shown in Examples 1, 7, 8, 9, 13, 18, and 34 had a serum PTH concentration of 100 pg / ml or less at 0 minutes increased to 400 pg / ml or more after 15 to 30 minutes. After 240 minutes, it was lowered to 150 pg / ml or less.
  • Example 1 2 ′-[(1R) -1-( ⁇ (2R) -3-[(2S) -2- (3-fluoro-4-methylbenzyl) pyrrolidin-1-yl] -2-hydroxypropyl ⁇ oxy) ethyl ] -3-Methylbiphenyl-4-carboxylic acid
  • Example 2 3 ′-[(1R) -1-( ⁇ (2R) -3-[(2S) -2- (3-fluoro-4-methylbenzyl) pyrrolidin-1-yl] -2-hydroxypropyl ⁇ oxy) ethyl ] -3-Methylbiphenyl-4-carboxylic acid (2a) (2R) -2- ⁇ [(1R) -1- (3-bromophenyl) ethoxy] methyl ⁇ oxirane (1R) -1- (3-bromo Phenyl) ethanol (503 mg, 2.50 mmol), (2R) -oxiran-2-ylmethyl 3-nitrobenzenesulfonate (843 mg, 3.25 mmol) was dissolved in N, N-dimethylformamide (12.5 mL) Sodium chloride (142 mg, 3.25 mmol) was added and stirred at room temperature for 2 hours.
  • reaction solution was filtered through Celite, and the filtrate was washed with water (x1) and saturated brine (x1), dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressure.
  • Example 3 2 ′-[(1R) -1-( ⁇ (2R) -3-[(2R) -2- (3-fluoro-4-methylbenzyl) azetidin-1-yl] -2-hydroxypropyl ⁇ oxy) ethyl ] -3-Methylbiphenyl-4-carboxylic acid (3a) tert-butyl (2S) -2-[(3-fluoro-4-methylphenyl) carbonyl] azetidine-1-carboxylate Eur. J. et al. Med. Chem. 2000, 35, 979-988.
  • Example 4-45 The compound of Example 4-45 was produced according to the production method described in Example 1-3.
  • the physicochemical data of the example compounds are shown below.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention porte sur un nouveau composé qui a une action antagoniste sur un récepteur du calcium. De manière spécifique, l'invention porte sur un composé représenté par la formule générale (I) ou sur un sel pharmacologiquement acceptable de celui-ci. (Dans la formule, les substituants sont définis comme suit : R1, R1', R2 et R3 représentent chacun un atome d'hydrogène ou similaire ; Ar représente un groupe phényle ou similaire ; n représente 1 ou similaire ; et m représente 1 similaire).
PCT/JP2010/055546 2009-03-31 2010-03-29 Composé biphényle-amine cyclique WO2010113860A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009-084858 2009-03-31
JP2009084858 2009-03-31

Publications (1)

Publication Number Publication Date
WO2010113860A1 true WO2010113860A1 (fr) 2010-10-07

Family

ID=42828149

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2010/055546 WO2010113860A1 (fr) 2009-03-31 2010-03-29 Composé biphényle-amine cyclique

Country Status (1)

Country Link
WO (1) WO2010113860A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2374794A1 (fr) * 2008-12-24 2011-10-12 Daiichi Sankyo Company, Limited Composés amine cycliques
CN110403925A (zh) * 2019-09-04 2019-11-05 深圳阿贝细胞科技有限公司 化学小分子4-氨基联苯在防治骨关节炎的应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004514659A (ja) * 2000-10-25 2004-05-20 スミスクライン・ビーチャム・コーポレイション カルシライティック化合物
WO2004094362A1 (fr) * 2003-04-23 2004-11-04 Japan Tobacco Inc. Antagoniste de casr
WO2004106295A2 (fr) * 2003-05-28 2004-12-09 Bristol-Myers Squibb Company Piperodines et pyrrolidines substituees utilisees comme modulateurs du recepteur de detection du calcium et procede correspondant
WO2006123725A1 (fr) * 2005-05-19 2006-11-23 Astellas Pharma Inc. Derive de pyrrolidine ou son sel

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004514659A (ja) * 2000-10-25 2004-05-20 スミスクライン・ビーチャム・コーポレイション カルシライティック化合物
WO2004094362A1 (fr) * 2003-04-23 2004-11-04 Japan Tobacco Inc. Antagoniste de casr
WO2004106295A2 (fr) * 2003-05-28 2004-12-09 Bristol-Myers Squibb Company Piperodines et pyrrolidines substituees utilisees comme modulateurs du recepteur de detection du calcium et procede correspondant
WO2006123725A1 (fr) * 2005-05-19 2006-11-23 Astellas Pharma Inc. Derive de pyrrolidine ou son sel

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2374794A1 (fr) * 2008-12-24 2011-10-12 Daiichi Sankyo Company, Limited Composés amine cycliques
EP2374794A4 (fr) * 2008-12-24 2013-07-17 Daiichi Sankyo Co Ltd Composés amine cycliques
CN110403925A (zh) * 2019-09-04 2019-11-05 深圳阿贝细胞科技有限公司 化学小分子4-氨基联苯在防治骨关节炎的应用
CN110403925B (zh) * 2019-09-04 2023-11-03 深圳丹伦基因科技有限公司 化学小分子4-氨基联苯在防治骨关节炎的应用

Similar Documents

Publication Publication Date Title
TWI836124B (zh) 拮抗ｌｐａ１受體之脲化合物
CN100439330C (zh) 芳族羟苯基和芳族硫基苯基衍生物
WO2004106280A1 (fr) Antagoniste de casr
CN101370380A (zh) 化合物
JP7279758B2 (ja) テトラヒドロナフタレン誘導体
US9353113B2 (en) Tetrahydrocarboline derivative
ES2307068T3 (es) Compuestos de trifeniletileno como modularores selectivos de receptores de estrogenos.
CN103958465B (zh) 苯基衍生物
US20100261772A1 (en) Cycloalkylidene Compounds As Selective Estrogen Receptor Modulators
EA009767B1 (ru) Производные пролина, обладающие сродством к альфа-2-дельта субъединице кальциевого канала
WO2010113860A1 (fr) Composé biphényle-amine cyclique
WO2007010885A1 (fr) Dérivé de propanamide substitué et composition pharmaceutique contenant celui-ci
JP2013213009A (ja) ヘテロ環含有インダニル化合物
JP5628687B2 (ja) インダニル化合物
JP2013213010A (ja) ヘテロ環含有環状アミン化合物
JP5551614B2 (ja) 環状アミン化合物
CN119403794A (zh) 用于治疗trpm3介导的病症的新型衍生物
JP2012017320A (ja) 環状アミン化合物を含有する医薬組成物
TW200416032A (en) Cathepsin cysteine protease inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10758631

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10758631

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载